Literature DB >> 9087504

In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.

N X Chin1, I Weitzman, P Della-Latta.   

Abstract

Fluvastatin, a cholesterol-lowering drug, exhibited minimal activity (MICs of 64 to >128 microg/ml) against Candida species and Cryptococcus neoformans. When fluvastatin was combined with fluconazole or itraconazole, both synergistic and additive effects were noted (fractional inhibitory concentration indices of < or = 0.156 to 0.625; fractional lethal concentration indices of < or = 0.156 to 0.75). This combined fungicidal activity was confirmed by time-versus-killing studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087504      PMCID: PMC163809     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Combination therapy in systemic mycosis.

Authors:  A Polak
Journal:  J Chemother       Date:  1990-08       Impact factor: 1.714

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Authors:  E M Johnson; D W Warnock; J Luker; S R Porter; C Scully
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

4.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

5.  Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro.

Authors:  E M Scott; V N Tariq; R M McCrory
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

6.  Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities.

Authors:  R Le Guennec; J Reynes; M Mallié; C Pujol; F Janbon; J M Bastide
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

  6 in total
  23 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 4.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

5.  Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.

Authors:  Elias K Spanakis; Themistoklis K Kourkoumpetis; Grigorios Livanis; Anton Y Peleg; Eleftherios Mylonakis
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

6.  Mevalonate governs interdependency of ergosterol and siderophore biosyntheses in the fungal pathogen Aspergillus fumigatus.

Authors:  Sabiha Yasmin; Laura Alcazar-Fuoli; Mario Gründlinger; Thomas Puempel; Timothy Cairns; Michael Blatzer; Jordi F Lopez; Joan O Grimalt; Elaine Bignell; Hubertus Haas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

7.  Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.

Authors:  Anne-Pauline Bellanger; Alexander M Tatara; Fazal Shirazi; Teclegiorgis Gebremariam; Nathaniel D Albert; Russell E Lewis; Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2016-03-16       Impact factor: 5.226

8.  Synergy of nitric oxide and azoles against Candida species in vitro.

Authors:  G E McElhaney-Feser; R E Raulli; R L Cihlar
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  New Approach For Simvastatin As An Antibacterial: Synergistic Effect With Bio-Synthesized Silver Nanoparticles Against Multidrug-Resistant Bacteria.

Authors:  E P Figueiredo; J M Ribeiro; E K Nishio; S Scandorieiro; A F Costa; V F Cardozo; A G Oliveira; N Durán; L A Panagio; Rkt Kobayashi; G Nakazato
Journal:  Int J Nanomedicine       Date:  2019-10-03

10.  Synergistic ROS-Associated Antimicrobial Activity of Silver Nanoparticles and Gentamicin Against Staphylococcus epidermidis.

Authors:  Paulina Mazur; Iwona Skiba-Kurek; Paulina Mrowiec; Elżbieta Karczewska; Ryszard Drożdż
Journal:  Int J Nanomedicine       Date:  2020-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.